The Role of Imaging in the Development of Oncologic Agents

A. Shields,P. Ho,J. Grierson

DOI: https://doi.org/10.1002/j.1552-4604.1999.tb05937.x

1999-08-01

Abstract:P to the development of metabolic imaging, researchers had to use in vitro measurements of tumor proliferation made with biopsy specimens obtained from patients. Many studies found such information predictive of the response to therapy and disease aggressiveness. Biopsies, however, may reflect the metabolism of only a small area of a tumor; they may not be representative and cannot easily be done repeatedly. In contrast, the power of positron emission tomography (PET) imaging is that it can quantitatively image tissues repeatedly in a noninvasive way. One can probe different pathways in tumor masses as determined by the appropriate choice of a metabolic tracer. The tracers are delivered in small doses in vivo under normal physiological conditions. This type of tailored noninvasive experimental design is not available with any other technique. Therefore, PET has emerged as a research tool to improve the evaluation of tumor treatment. [F-18]labeled fluorodeoxyglucose (FDG) is the most commonly used agent to diagnose tumors. Preliminary investigations of the use of FDG to measure response to therapy have been promising. While measuring tumor energetics may be of interest, we think that more specific measures of tumor metabolic pathways and proliferation will provide better information to predict and monitor response to therapy. To that end, our studies have concentrated on imaging tumor proliferation with thymidine and its analogs. We have worked on developing the tools needed to measure treatment response with PET and begun to incorporate these tools in the early trials of new oncologic agents. DEVELOPMENT OF NEW ONCOLOGIC AGENTS